Antibody-drug Conjugates & Bioconjugates

PARTNERING & PIPELINE

Catalent Biologics offers flexible options for our partners to employ SMARTag® technology in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services.

Please click here to inquire about potential SMARTag® collaboration opportunities:

• Licensing an asset from our pipeline (including molecules against both solid and hematopoietic tumors)
• Collaborating with us to develop de novo assets using our SMARTag® platform technology and ADC development expertise